Article

Sustained-release formula in works for neovascular AMD

PR Pharmaceuticals Inc. (PRP) and OSI Pharmaceuticals entered an agreement to develop a sustained-release formula of pegaptanib sodium injection (Macugen), a novel treatment for neovascular age-related macular degeneration.

The agreement gives OSI and its development and marketing partner Pfizer access to PRP's proprietary ProPhase technology for encapsulating pegaptanib sodium injection for ophthalmic use. OSI's eye disease unit, Eyetech Pharmaceuticals, is responsible for clinical development activities and has the right to manufacture and commercialize the resulting product.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.